Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Providing Biomarker Services to Eisai

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences today announced a contract with Japanese drug firm Eisai to provide biomarker services for Alzheimer's disease.

Under the terms of the deal, Proteome Sciences, based in Surrey, UK, will measure candidate biomarkers for AD using its AD-TMT-SRM assay set on human samples, it said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.